66
Participants
Start Date
July 1, 2024
Primary Completion Date
August 22, 2028
Study Completion Date
October 12, 2029
LCAR-M61S cells preparation
"Biological:~LCAR-M61S or LCAR-M61D cells intravenous infusion; Prior to infusion of the LCAR-M61S and LCAR-M61D cell preparation, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine."
LCAR-M61D cells preparation
"Biological:~LCAR-M61S or LCAR-M61D cells intravenous infusion; Prior to infusion of the LCAR-M61S and LCAR-M61D cell preparation, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine."
Beijing Gobroad Hospital, Beijing
Jiangsu Province Hospital, Nanjing
Anhui Cancer Hospital, Hefei
Henan Cancer Hospital, Zhengzhou
Collaborators (1)
Nanjing Legend Biotech Co.
INDUSTRY
The First Affiliated Hospital with Nanjing Medical University
OTHER